Skip main navigation

Mixed Views on US Biosimilar Market


Please take some time to review this article: Mixed views on US biosimilar market

Much was expected of biosimilars and their potential to cut the price of originator with savings projected to reach hundreds of billions. Such expectation at least in the US have proven unrealistic. A report last year (2019) outlined that the US healthcare system barely make savings worth 7 billion dollars annually. AS 2020 makes its halfway, researchers begin to investigate biosimilars in the US to determine how successful their introduction onto the market could be.

Review the following reference and probe the questions below:

How many TFDA approved biosimilars are there on the Taiwan market? What is the reimbursement policy for biosimilars in Taiwan as dictated by the National Insurance of Health?

This article is from the free online

Pharmacotherapy: Understanding Biotechnology Products

Created by
FutureLearn - Learning For Life

Our purpose is to transform access to education.

We offer a diverse selection of courses from leading universities and cultural institutions from around the world. These are delivered one step at a time, and are accessible on mobile, tablet and desktop, so you can fit learning around your life.

We believe learning should be an enjoyable, social experience, so our courses offer the opportunity to discuss what you’re learning with others as you go, helping you make fresh discoveries and form new ideas.
You can unlock new opportunities with unlimited access to hundreds of online short courses for a year by subscribing to our Unlimited package. Build your knowledge with top universities and organisations.

Learn more about how FutureLearn is transforming access to education